한글목차

개요

세계 후만증 치료 시장은 2023년 13억 달러에 달러에 달했고, 2024-2031년의 예측 기간 동안 연평균 6.2% 성장하여 2031년에는 21억 달러에 달할 것으로 전망됩니다.

후만증은 척추가 휘어져 등 위쪽이 정상보다 둥글게 보이는 척추 만곡증입니다. 허리 통증과 근육 경직을 유발할 수 있습니다. 비수술적 치료와 수술적 치료 옵션이 있습니다.

후만증은 젊은 사람부터 노인까지 걸릴 수 있습니다. 후만증은 다양한 문제로 인해 발생하며, 환자마다 그 영향도 다릅니다. 척추 후만증은 척추의 퇴행성 질환(관절염, 디스크 변성 등), 골다공증으로 인한 골절(골다공증성 압박골절), 부상(외상)으로 인해 발생할 수 있습니다.

시장 역학 :

성장 촉진요인과 저해요인

치료 옵션의 발전

물리치료, 보조기 및 통증 관리 기술은 비침습적 치료를 선호하는 환자들에게 실용적인 대안을 제공하기 위해 진화하고 있으며, 그 결과 전체 치료 분야가 확대되고 있습니다. 줄기세포 치료나 다혈소판 혈장(PRP) 주사와 같은 생물학적 발전은 손상된 조직을 치유하고 재생시켜 후만증 환자들에게 더 나은 결과를 가져다 줄 수 있습니다.

특히 척추 정렬을 촉진하는 것을 목표로 하는 혁신적인 정형외과 기구 및 보조기구의 개발은 치료 효과와 환자의 편안함을 향상시켜 그 사용을 촉진할 수 있습니다. 척추후만증에 대한 맞춤 치료 접근법은 더 나은 관리, 더 높은 환자 만족도, 더 나은 결과를 가져옵니다.

인식 부족

증상 및 사용 가능한 치료 옵션에 대한 인식 부족은 시장 성장과 확대에 걸림돌이 될 것으로 예상됩니다. 환자들은 수술적 치료와 비수술적 치료 모두에 대한 치료 옵션을 알지 못할 수 있으며, 그 결과 삶의 질을 향상시킬 수 있는 효과적인 치료법을 충분히 활용하지 못할 수 있습니다.

목차

제1장 조사 방법과 조사 범위

제2장 정의와 개요

제3장 주요 요약

제4장 시장 역학

• 영향요인
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 영향 분석

제5장 산업 분석

• Porter의 Five Forces 분석
• 공급망 분석
• 가격 분석
• 규제 분석
• 상환 분석
• 특허 분석
• SWOT 분석
• DMI의 견해

제6장 유형별

• 자세 후만증
• 슈어만 후만증
• 선천성 후만증

제7장 치료 유형별

• 약제
  • Aspirin
  • Ibuprofen
  • Naproxen
  • Acetaminophen
  • 기타
• 디바이스
• 기타

제8장 유통 채널별

• 병원 약국
• 온라인 약국
• 소매 약국
• 기타

제9장 지역별

• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타 유럽
• 남미
  • 브라질
  • 아르헨티나
  • 기타 남미
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 한국
  • 기타 아시아태평양
• 중동 및 아프리카

제10장 경쟁 구도

• 경쟁 시나리오
• 시장 현황/점유율 분석
• 인수합병(M&A) 분석

제11장 기업 개요

• Salo Orthotics
  • 기업 개요
  • 제품 포트폴리오와 설명
  • 재무 개요
  • 주요 발전
• AdvaCare Pharma
• Boston Orthotics & Prosthetics
• ScoliBrace
• ALIMCO
• NuVasive, Inc.
• Stryker Corporation
• Mallinckrodt Pharmaceuticals
• Wellona Pharma
• Bayer AG.

제12장 부록

영문목차

Overview

Global Kyphosis Treatment Market reached US$ 1.3 billion in 2023 and is expected to reach US$ 2.1 billion by 2031, growing at a CAGR of 6.2% during the forecast period 2024-2031.

Kyphosis is the curvature of the spine that causes the top of the back to appear more rounded than normal. It might cause back pain and stiff muscles. There are nonsurgical and surgical treatment options available.

Kyphosis can affect the young and the old. It is brought on by different problems and can affect each patient differently. Kyphosis can be caused by degenerative diseases of the spine (such as arthritis or disk degeneration) as well as fractures caused by osteoporosis (osteoporotic compression fractures) and injury (trauma).

Market Dynamics: Drivers & Restraints

Advancements in treatment options

Physical therapy, bracing, and pain management techniques have evolved to give practical alternatives for patients who prefer non-invasive treatments, therefore expanding the entire therapeutic field. Biologic advancements such as stem cell therapy and platelet-rich plasma (PRP) injections can heal and regenerate tissues that have been damaged, resulting in better outcomes for kyphosis patients.

The development of innovative orthopedic devices and braces intended specifically to promote spinal alignment can improve therapy efficacy and patient comfort, hence boosting their use. Personalized treatment approaches for kyphosis result in improved management, higher patient satisfaction, and better outcomes.

Lack of awareness

Lack of awareness about the condition as well as the available treatment options is expected to hinder market growth and expansion. Patients might be unaware of the available treatment alternatives, both surgical and non-surgical, resulting in the underuse of effective therapies that could improve their quality of life.

Segment Analysis

The global kyphosis treatment market is segmented based on type, treatment type, distribution channel and region.

Scheuermann's kyphosis segment is expected to dominate the market share

The Scheuermann kyphosis segment holds a major portion of the market share and is anticipated to continue this trend during the forecast period. This is attributed to the increase in the geriatric population and incidences of the Scheuermann kyphosis diseases. Scheuermann's kyphosis (kye-FOH-sis) is an upper back condition. It gives the upper back a rounded appearance, giving the appearance of being hunched over. Scheuermann's disease is another name for it.

For instance, according to the report published by the National Institute of Health in 2023, it is stated that the prevalence of the disease in the United States is 1% to 8%. This increasing incidence is expected to contribute to the overall market growth. Increasing Scheuermann's kyphosis increases the demand for the treatment of the disease

Geographical Analysis

North America is expected to hold a significant position in the kyphosis treatment market share

North America is anticipated to dominate the kyphosis treatment market, globally. The factors attributed to the high growth of the region are the increasing number of kyphosis cases, increase in technological advancement, increase in genetic disorders and increase in geriatric population.

For instance, according to the report published by the National Institute of Health in 2023, it is stated that Scheuermann's Kyphosis (SK) is a rigid spinal kyphosis, which can occur the most and can contribute to the regional market expansion.

In addition, increasing strategies such as mergers and acquisitions and partnerships within key market players are expected to strengthen their product portfolio which will drive the market. Also, several product launches in the market will lead to lucrative growth of the market.

Market Segmentation

By Type

• Postural Kyphosis
• Scheuermann's Kyphosis
• Congenital Kyphosis

By Treatment Type

• Drugs
  • Aspirin
  • Ibuprofen
  • Naproxen
  • Acetaminophen
  • Others
• Devices
• Others

By Distribution Channel

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Salo Orthotics, AdvaCare Pharma, Boston Orthotics & Prosthetics, ScoliBrace, ALIMCO, NuVasive, Inc., Stryker Corporation, Mallinckrodt Pharmaceuticals, Wellona Pharma and Bayer AG among others.

Why Purchase the Report?

• To visualize the global kyphosis treatment market segmentation based on type, treatment type, distribution channel, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of kyphosis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global kyphosis treatment market report would provide approximately 53 tables, 47 figures, and 176 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Treatment Type
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Advancements in treatment options
  • 4.1.2. Restraints
    • 4.1.2.1. Lack of awareness
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Reimbursement Analysis
• 5.6. Patent Analysis
• 5.7. SWOT Analysis
• 5.8. DMI Opinion

6. By Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Postural Kyphosis*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Scheuermann's Kyphosis
• 6.4. Congenital Kyphosis

7. By Treatment Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 7.1.2. Market Attractiveness Index, By Treatment Type
• 7.2. Drugs*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.2.3. Aspirin
  • 7.2.4. Ibuprofen
  • 7.2.5. Naproxen
  • 7.2.6. Acetaminophen
  • 7.2.7. Others
• 7.3. Devices
• 7.4. Others

8. By Distribution Channel

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.1.2. Market Attractiveness Index, By Distribution Channel
• 8.2. Hospital Pharmacies*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Online Pharmacies
• 8.4. Retail Pharmacies
• 8.5. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
    • 9.2.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.2.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.2.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.3.1. The U.S.
    • 9.2.3.2. Canada
    • 9.2.3.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
    • 9.3.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.3.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.4.1. Germany
    • 9.3.4.2. UK
    • 9.3.4.3. France
    • 9.3.4.4. Italy
    • 9.3.4.5. Spain
    • 9.3.4.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
    • 9.4.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.4.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.4.1. Brazil
    • 9.4.4.2. Argentina
    • 9.4.4.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
    • 9.5.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.4.1. China
    • 9.5.4.2. India
    • 9.5.4.3. Japan
    • 9.5.4.4. South Korea
    • 9.5.4.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
    • 9.6.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Salo Orthotics*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. AdvaCare Pharma
• 11.3. Boston Orthotics & Prosthetics
• 11.4. ScoliBrace
• 11.5. ALIMCO
• 11.6. NuVasive, Inc.
• 11.7. Stryker Corporation
• 11.8. Mallinckrodt Pharmaceuticals
• 11.9. Wellona Pharma
• 11.10. Bayer AG.

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us